Status:
UNKNOWN
Evaluataion of NOAC Levels in Acute Stroke
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Ischemic Stroke
Anticoagulant Adverse Reaction
Eligibility:
All Genders
20+ years
Brief Summary
Non-vitamin K antagonist oral anticoagulants (NOACs) are recommended over warfarin in preventing stroke and thromboembolism among patients with atrial fibrillation (AF) in several guidelines. To evalu...
Detailed Description
Non-vitamin K antagonist oral anticoagulants (NOACs) are recommended over warfarin in preventing stroke and thromboembolism among patients with atrial fibrillation (AF) in several guidelines. To evalu...
Eligibility Criteria
Inclusion
- Age ≥ 20 years
- Having AF diagnosis
- Under NOACs therapy including dabigatran, rivaroxaban, apixaban and edoxaban.
- Admitted for acute IS, transient ischemic attack (TIA), ICH or major bleeding
Exclusion
- The ICH is resulted from trauma.
- Decline the inform consent.
Key Trial Info
Start Date :
May 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT06144866
Start Date
May 1 2020
End Date
December 1 2025
Last Update
November 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan, 100